<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03644381</url>
  </required_header>
  <id_info>
    <org_study_id>MP-CUSM-12-090-PED</org_study_id>
    <nct_id>NCT03644381</nct_id>
  </id_info>
  <brief_title>Milk Desensitization in Children</brief_title>
  <official_title>Milk Desensitization and Induction of Tolerance in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess a novel and potentially life-changing therapy, by actively treating
      Cow's Milk Allergy (CMA) using Oral Immunotherapy, which may allow patients to safely consume
      milk and other dairy products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized control study with a cross-over design. Eighty four boys and girls with
      between 6 to 20 years of age, diagnosed with IgE-mediated cow's milk allergy using strict
      skin testing and serological criteria, will be recruited for this study. 42 will undergo oral
      immunotherapy, while 42 will be followed as natural history controls but will be offered
      similar therapy, should it be successful, at the completion of one year. OIT subjects will
      initaiate therapy with a 2-day rush desensitization treatment using oral doses of milk, in
      the investigator's Clinical Investigation Unit. They will then continue the highest tolerated
      dose of milk at home for two weeks. Subsequently, they will return for weekly increases in
      doses until a maximum of 200 ml of milk is ingested daily. The primary clinical outcome will
      be a comparison of the amount of milk consumed safely on oral challenge performed prior to
      OIT, when the OIT dose has reached its maximum (200 ml or highest tolerated dose) and after
      one year of therapy. Patients will also be followed with clinical symptom scores and adverse
      event diarie. Their immunological parameters such as changes in milk-specific IgE, blocking
      antibodies (IgG4 and IgA) and regulatory T and B cells will also be monitored. It is expected
      that there will be important improvement in the ability to safely ingest milk and other dairy
      products, and this will be accompanied by significant decreases in IgE and increases in
      Regulatory T and B cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2013</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence or absence of allergic symptoms during an oral challenge to milk</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of participants randomized to treatments arms who achieve milk desensitization compared to participants randomized to the control groups. This is measured by whether a participant is able to tolerate a total dose of 300 ml of milk during an oral food challenge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over the immunotherapy process of milk specigic IgE levels</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of milk specigic IgE before, during and after the desensitization process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over the immunotherapy process of milk specigic IgA levels</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of milk specigic IgA before, during and after the desensitization process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over the immunotherapy process of milk specigic IgG4 levels</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of milk specigic IgG4 before, during and after the desensitization process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over the immunotherapy process of milk specigic IgE glycosylation levels</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of milk specigic IgE glycosylation before, during and after the desensitization process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over the immunotherapy process of mast cell activation as measured by CD63 expression</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of mast cell activation as measured by CD63 expression before, during and after the desensitization process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over the immunotherapy process of of DNA methylation levels</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of DNA methylation levels before, during and after the desensitization proces</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over the immunotherapy process of Regulatory T cell levels</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of Regulatory T cell levels, before, during and after the desensitization process</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Cow Milk Allergy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following randomization, participants in this group will receive escalating doses milk, up to a daily dose of 200 ml. Once they attain that dose, they will maintain it for one month. At the end of this period, they will undergo a open challenge to 300 ml of milk. They will then enter a year-long follow-up period</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Immunotherapy</intervention_name>
    <description>Starting from a very low level and over a period of several months, participants in the treatment group receive escalating doses of milk. Participants will also have blood and saliva draws to assess parameters of their immune system as well as skin prick testing</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A history suggestive of IgE-mediated allergy to milk. An IgE-mediated reaction to a
             specific food is defined as a minimum of 2 mild symptoms and/or 1 moderate and/or 1
             severe symptom that began within 1-20 minutes after ingestion or contact. Mild
             IgE-mediated symptoms include: pruritus, urticaria, flushing, or rhinoconjunctivitis.
             Moderate symptoms include angioedema (of face or lips), throat tightness,
             gastrointestinal complaints (vomiting, cramping, pain and/or diarrhea), or airway
             involvement (cough, nasal blockage, mucous ); severe symptoms include bronchospasm,
             wheezing, hypoxia, cyanosis, low blood pressure, or circulatory collapse (shock)
             (appendix A ,table 1) (61).

          2. The presence of at least one of the following confirmatory tests:

               -  (a) Positive skin prick test to milk (weal diameter 3 mm larger than that of the
                  normal saline control). The allergen used will be commercially available milk
                  extracts (Omega Labs, Montreal, QC). Skin tests will traced in ink, tape
                  transferred to paper and wheal diameter measured by computer assisted planometry.

               -  (b) Detection of serum specific IgE (&gt;0.35 kU/L) to milk or any of its proteins,
                  measured by fluorescence enzyme immunoassay (Immunocap, Phadia, Uppsala, Sweden).
                  The range for Immuncap is 0.35 - 100 and changes over time can be monitored
                  effectively.

          3. Informed consent form signed by the parents or legal guardian

        Exclusion Criteria:

          1. Patients with uncontrolled asthma or other uncontrolled respiratory diseases .

          2. Malignancies, autoimmune diseases and/or severe primary or secondary immune
             deficiencies.

          3. Patients receiving immunosuppressive therapy.

          4. Patients receiving Î²-blockers (including topical formulations).

          5. Associated diseases contraindicating the use of epinephrine: cardiovascular disease or
             severe hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Duncan Lejtenyi, M.Sc</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>22369</phone_ext>
    <email>duncan.lejtenyi@muhc.mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Lee</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>67096</phone_ext>
    <email>jennifer.lee@muhc.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MUHC</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan Lejtenyi, MSc</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>22369</phone_ext>
      <email>duncan.lejtenyi@muhc.mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Lee</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>67096</phone_ext>
      <email>jennifer.lee@muhc.mcgill.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Bruce Mazer</investigator_full_name>
    <investigator_title>Executive Director and CSO (Interim)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milk Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03644381/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03644381/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

